 - Because of rapid clinical progression and decline at time of relapse in patients with grade IV gliomas and DIPGs, and the 4-6 weeks required to develop vaccine, patients with these tumors will be eligible to enroll and have DCs harvested and stored at the time of diagnosis, but will not be treated with vaccine until time of relapse. 